ARTEMIC CHANGING EVERYTHING

AS THE STRUGGLE CONTINUES AGAINST THE PANDEMIC OF OUR LIFETIME, HEALTHCARE SYSTEMS ACROSS THE GLOBE ARE IN NEED OF SUPPORT. ARTEMIC[™] IS THE FIRST FOOD SUPPLEMENT CLINICALLY TESTED TO HELP COVID-19 SYMPTOMS FROM DETERIORATING.

ARTEMIC HAS UNLIMITED POTENTIAL AS AN EVERYDAY TREATMENT THAT CAN BE TAKEN AT HOME, AS WELL AS IN A CLINICAL SETTING. BY PREVENTING THE CYTOKINE STORM EFFECT FROM RAVAGING A PATIENT'S BODY, ARTEMIC PROMISES TO BE A VALUABLE WEAPON AGAINST NOT ONLY COVID-19, BUT A WIDE RANGE OF DISEASES THAT THREATEN HUMAN HEALTH.

ARTEMIC RESCUE - CLINICALLY TESTED TO EFFECTIVELY REDUCE THE INFLAMMATION OF CELL TISSUE AND PREVENT THE INCUBATED PRODUCTION OF THE CYTOKINES THAT CAUSE UNCONTROLLED INFLAMMATION.

Committed to life-

IMPORTANT NOTICE - FOR EDUCATIONAL AND INFORMATIONAL PURPOSES ONLY.

THE INFORMATION CONTAINED IN THIS BROCHURE IS STRICTLY FOR EDUCATIONAL AND INFORMATIONAL PURPOSES ONLY. IT SPECIFICALLY DOES NOT CONSTITUTE MEDICAL ADVICE OR ANY SUGGESTION AS TO HOW ANY PRODUCT OR INGREDIENT REFERENCED MIGHT BE USED TO PREVENT, TREAT OR CURE ANY DISEASE, PAIN, DEFORMITY, INJURY, OR PHYSICAL OR MENTAL CONDITION. ONLY AN AUTHORISED HEALTH CARE PROFESSIONAL (E.G. MEDICAL DOCTOR, PHARMACIST) CAN RECOMMEND OR PRESCRIBE TREATMENTS THAT ARE INTENDED TO TREAT OR PREVENT ANY DISEASE, DISORDER, OR CONDITION. IF YOU KNOW OR THINK YOU ARE INFECTED WITH SARS-COV-2 AND PARTICULARLY IF YOU ARE SUFFERING POSSIBLE SYMPTOMS OF COVID-19, PLEASE CONTACT AN AUTHORISED HEALTH CARE PROFESSIONAL FOR ADVICE OR TREATMENT WITH MINIMUM DELAY.

Distributed in the USA by AMC Pharma USA, LLC 201 E. Kennedy Blvd, Suite 1611, Tampa FL 33602 www.amcpharma-usa.com; info@amcpharma-usa.com 813.508.0160

HIGHLY EFFECTIVE IN A SMALL DOSAGE

STUDIES HAVE SHOWN THAT ARTEMIC INGREDIENTS CAN HAVE THE FOLLOWING EFFECTS



Anti-inflammatory reduces inflammation, including from the cytokine storm effect



Mitochondrial function Strengthens and regulates mitochondrial function, possibly helping to reduce the aftereffects seen in Long COVID-19



Anti-microbial staves off additional infection from bacteria





Immunomodulatory enhances the body's immune response and prevents the onset of the sometimes-deadly cytokine storm effect



Prevents blood clotting

EVIDENCE BASED:

There are **127,959 studies** on Vitamin C* There are **46,634 studies** on Curcumin* There are **26,819 studies** on Artemisia* There are **2,222 studies** on Boswellia Serrata*



FORMULATION

A ground-breaking new supplement has clinically shown to be able to protect against the worsening of symptoms of COVID-19, that make the virus so dangerous, by targeting the immune response. Highly effective with only a small dosage, Phase II clinical trials confirm that this all-natural formulation can prevent a patient's condition from deteriorating and significantly improving the symptoms after 2 days of treatment.

Until now, every new COVID-19 infection has increased the odds that the healthcare system would become overwhelmed and patients would no longer be able to access the care they need. With the support of ArtemiC Rescue[™], a pioneering supplement developed by MGC Pharmaceuticals and powered by Swiss PharmaCan's patented MyCell[™] technology, people will reduce the need for additional medical support and the risk of becoming life threatening.

ArtemiC is a revolutionary food supplement that brings together the powerful anti-viral properties of four natural ingredients. To bring the fight directly to the cells and ensure the body can properly utilize every drop of the formulation, it uses patented MyCell[™] technology to boost bioavailability and cellular absorption.



100% PURE AND NATURAL ACTIVE INGREDIENTS



CLINICALLY PROVEN



HIGHLY EFFECTIVE IN A SMALL DOSAGE

ARTEMIC HAS SHOWN TO REDUCE THE SYMPTOMS OF COVID-19 AND THE CYTOKINE STORM EFFECT -SMOTHERING AND OBSTRUCTING ITS PROGRESS IN MULTIPLE WAYS.

Committed to fife-

WHEN THE IMMUNE SYSTEM OVERREACTS TO A VIRUS, IT CAN BE MORE DANGEROUS THAN THE VIRUS ITSELF


HOW IT WORKS

Current research suggests that our own immune systems may be the cause for the severe illness some patients experience after being infected with COVID-19. This is due to the overreaction of immune system that causes more problems than the virus itself.

We have known since the SARS epidemic of 2003 that a significant number of deaths associated with viral infection can be traced to a phenomenon known as the cytokine storm. This occurs when replication of the virus inside the body leads to an excessive inflammatory response. Cytokines are biological chemicals that are used to stimulate cell pathways and communication between cells. Their main job is to signal the immune system to fight off an infection. For instance, some cytokines make your blood clot more easily while others help with antibody production.

However, when an excess of the chemicals responsible for controling your inflammatory response are released, a cytokine storm can occur, causing high levels of inflammation at their location in the body. This leads to a cascade effect that can be extremely dangerous and, in some cases, even fatal.

The cytokine storm effect is now thought to have been responsible for the disproportionate number of healthy young adults who died during the 1918 Spanish Flu epidemic, as well as deaths from the bird flu H5N1 and hantavirus pulmonary syndrome, among others. It is not a disease in itself, but a serious medical issue that can cause extreme damage, sometimes even leading to organ failure and death. ArtemiC is designed specifically to tackle this issue, helping your body fight the symptoms of the disease itself while blocking the overreaction that can cause the situation to quickly deteriorate.



COVID 19 DISEASE PROGRESSION



CLINICALLY TESTED

IN A PHASE II CONTROLLED CLINICAL STUDY DESIGNED TO EVALUATE THE EFFECT OF ARTEMIC[™] IN PATIENTS DIAGNOSED WITH COVID-19


ArtemiC was tested for safety and efficacy in a double-blind, placebo-controlled clinical trial involving 50 patients diagnosed with COVID-19. In a Phase II clinical trials, ArtemiC statistically improved the recovery of patients infected with COVID-19. All patients had a confirmed COVID-19 infection, were hospitalized in a stable, moderate condition and were between the ages of 40 and 75.

By the end of the two-week trial, 100% of the patients in the treatment group had shown improvement. Within 15 days of follow-up, all had fully recovered. No patients in the treatment group required additional medical intervention and no adverse reactions to the treatment were recorded.

Those who were treated with ArtemiC showed:

- 100% met all FDA primary and secondary end points
- Improved clinical recovery
- Improvement of symptoms and pain
- Faster overall recovery time
- No requirement for additional medical assistance (ICU, ventilation).

CLINICAL TRIAL SCHEDULE DIAGRAM




GENERAL HEALTH STATUS

In this study, a scoring system called NEWS2* is used to grade COVID-19 symptoms to see if the patient's condition is worsing. If the condition was getting worse, patients might need more intensive care.

The NEWS2 score of 18 out of those 33 (60%) patients treated with ArtemiC remained stable throughout the study. Out of these patients with a stable score, 13 had the lowest score possible (0) and remained with that score throughout. Another 12 out of the 33 patients treated with ArtemiC had improvements in their NEWS2 scores as time went by. Therefore, only 3 (9%) of the patients treated with ArtemiC showed worsening NEWS2 scores at any point during the study. In contrast, 6 of the 17 patients (35%) treated with the placebo spray had worsening NEWS2 scores as time went by.

The diagram «ArtmiC Effect» shows the average NEWS2 scores of patient treated with ArtemiC (green line) and of patients treated with the placebo spray (magenta line). On average, the scores improved (decreased) over the 15 days after ArtemiC treatment and got worse (increased) after placebo treatment.


ARTEMIC EFFECT DIAGRAM



BLOOD OXYGEN LEVELS

At the beginning of the study, when patients were first hospitalized, 11 of the 33 patients (33%) who were going to be treated with ArtemiC had abnormal oxygen levels blood oxygen levels. Nine days after treatment, only 1 patient of the 33 patients (3%) still had abnormal oxygen levels in their blood. In contrast, at the beginning of the study, 7 out of the 17 patients (41%) who were going to be given the placebo treatment had abnormal oxygen levels. Nine days after starting the treatment, there were still 4 out of 17 patients (24%) who had abnormal oxygen levels in their blood.

PATIENTS WITH ABNORMAL OXYGEN LEVEL IN BLOOD




FEVER

None of the patients treated with ArtemiC had fever after the ninth day of the study. In the group of patients treated with the placebo spray, there was still one patient with a fever on day 12 of the study.


Some patients in each treatment group needed oxygen support. The time on oxygen support was much shorter for patients who had been treated with ArtemiC in comparison to the patients treated with the placebo. The patients who had been treated with ArtemiC needed oxygen support for an average of 2.5 days. The patients who were treated with placebo spray needed oxygen support for an average of 7.5 days.

Two out of the 17 patients treated with placebo suffered from a serious deterioration in their health status and needed mechanical ventilation. None of the 33 patients treated with ArtemiC needed mechanical ventilation.

AVERAGE NR OF DAYS FOR OXYGEN SUPPORT



PATIENTS WITH MECHANICAL VENTILATION



POWERED BY MYCELL™ TECHNOLOGY PURE BIOAVAILABILITY

Committed to fife-



Four active ingredients make ArtemiC an effective anti-viral treatment, but they share one major flaw: all have poor bioavailability when taken orally.

- Bioavailability for vitamin C is less than 50% at higher doses, while oral administration even in high quantities cannot raise blood concentration above 0.22 mM.
- Boswellia Serrata has low oral bioavailability because it is lipophilic in nature and insoluble in intestinal fluid.
- Curcumin exhibits very poor bioavailability, with many studies showing low or even undetectable concentrations in the blood due to its poor absorption, rapid metabolism, chemical instability and rapid systemic elimination.

That's where our award-winning, patented technology comes in. The MyCell[™] delivery system increases the effectiveness of the ingredients used in ArtemiC, boosting the supplement's ability to assist the body in its fight against COVID-19 and other viral infections.



Botanical Extract

Botanical Extract in Water

Emulsion

MyCell encapsulated Botanical Extract

MyCell makes it possible to place a "skin" around oily substances that allows the active ingredients to be absorbed directly by the body's cells. ArtemiC is thus in perfect harmony with the body, efficient and unique not only as a formulation, but also as a technology. The encapsulated droplets target the cell and permeate the cell membrane for instant absorption, which is caused by:

- 100% water solubility
- Protection of active ingredients against gastric fluids
- Highest bioavailability

 sub-lingual and intestinal absorption
 no first-pass-effect liver
- Highest and fastest bioactitivity (cellular absorption)

FOUR INGREDIENTS ARE BROUGHT TOGETHER IN AN INTELLIGENT, HIGHLY EFFECTIVE FORMULATION ABLE TO TACKLE THE EFFECTS THE COVID-19 VIRUS CAN HAVE ON THE HUMAN BODY

ONLY PURE AND NATURAL ACTIVE INGREDIENTS

CRAFTED FROM CAREFULLY SELECTED PLANT PARTS OF CURCUMA LONGA, ARTEMISIA AND BOSWELLIA SERRATA ENHANCED WITH VITAMIN C

- Curcumin: Anti-viral activity comes from the inhibition of critical steps in viral replication, binding of the virus to the host cell and genome replication. Curcumin detects inflammation in the body and is a powerful anti-inflammatory agent, as well as creating antioxidant capacity.
- Boswellia Serrata: Research has repeatedly demonstrated that the substances contained in the resin of frankincense have considerable potential as a treatment for diseases and viral infections. For example, Boswellia Serrata penetrates the cells and kills the foreign invaders that cause infection.
- Artemisia L.: Exhibits anti-inflammatory, antioxidant, antispasmodic, antimicrobial, insecticidal, antimalarial, antifungal, and antioxidant properties.
- Vitamin C: Improves the body's immune response and protects against foreign invaders.



Curcuma · Vitamin C · Artemisia · Bosellia Serrata

Distributed in the US by AMC Pharma USA, LLC 201 East Kennedy Blvd, Ste 1611, Tampa, FL 33602 info@amcpharma-usa.com